Clinical characteristics of and growth hormone treatment effects on short stature with type 1 insulin-like growth factor receptor (IGF1R) gene alteration

• Published in: Endocrine Journal Vol. 71; no. 7; pp. 687 - 694
• Main Authors: Fujimoto, Masanobu, Wada, Keisuke, Kawashima-Sonoyama, Yuki, Yamamoto, Kei, Namba, Noriyuki, Taketani, Takeshi
• Format: Journal Article
• Language: English
• Published: Japan The Japan Endocrine Society 01.01.2024; Japan Science and Technology Agency
• Subjects: Adolescent; Body Height - drug effects; Child; Child, Preschool; Chromosome 15; Chromosome deletion; Clinical trials; Dwarfism - drug therapy; Dwarfism - genetics; Endocrinology; Female; Gene deletion; Genetic screening; Genetic testing; GH therapy; Growth Disorders - drug therapy; Growth Disorders - genetics; Growth hormones; Human Growth Hormone - therapeutic use; Humans; Infant, Small for Gestational Age - growth & development; Insulin-like growth factor 1 receptor (IGF1R); Insulin-like growth factor I; Insulin-Like Growth Factor I - metabolism; Insulin-like growth factor I receptors; Insulin-like growth factors; Japan; Male; Neurodevelopmental disorders; Patients; Pediatrics; Receptor, IGF Type 1 - genetics; Short stature; Treatment Outcome; Japan; GH therapy; Short stature; Insulin-like growth factor 1 receptor (IGF1R)
• ISSN: 0918-8959; 1348-4540; 1348-4540
• DOI: 10.1507/endocrj.EJ23-0680

Short stature with IGF-1 receptor (IGF1R) gene alteration is known as small-for-gestational-age (SGA) short stature with elevated serum IGF1 levels. Its prevalence and clinical characteristics remain unclear. No adapted treatment is available for short stature related to IGF1R gene alteration in Japan, and genetic testing is not yet widely accessible. We investigated short stature with IGF1R gene alterations and analyzed the clinical data of 13 patients using the results of questionnaires issued to the Japanese Society for Pediatric Endocrinology. Four cases were caused by a deletion of chromosome 15q26.3, and eight were caused by heterozygous pathogenic variants in the IGF1R gene. Cases with deletions showed a more severe degree of growth impairment (–4.5 ± 0.43 SD) than those caused by pathological variants (–2.71 ± 0.15 SD) and were accompanied by neurodevelopmental delay. However, cases caused by pathological variants lacked distinctive features. Only three of the 12 cases demonstrated serum IGF1 values exceeding +2 SD, and the other three had values below 0 SD. Four patients did not meet the criteria for SGA at birth. Six patients received GH therapy for SGA short stature and showed improvement in growth rate without any side effects or elevated serum IGF1 levels during treatment. Elevated IGF1 levels (over +2 SD) after GH treatment should be considered a suspicious finding. Owing to the lack of distinctive features, there was a possibility of undiagnosed cases of this condition. Promoting genetic testing and clinical trials on GH administration for this condition is recommended.